Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four-and 48-week results from a 6-month randomized trial

World Journal of Biological Psychiatry

Volumn 15, Issue 3, 2014, Pages 229-241

  Cordes, Joachim ^a   Thünker, Johanna ^a   Regenbrecht, Gunnar ^a   Zielasek, Jürgen ^a   Correll, Christoph U ^f,g   Schmidt Kraepelin, Christian ^a   Lange Asschenfeldt, Christian ^a   Agelink, Marcus W ^b   Kahl, Kai G ^c   Gaebel, Wolfgang ^a   Klimke, Ansgar ^d   Hauner, Hans ^e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Klinikum Offenbach GmbH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Olanzapine; Prevention; Schizophrenia; Weight management

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; LIPID; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIETITIAN; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH PROGRAM; HEART RATE; HUMAN; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; METABOLIC PARAMETERS; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF MONITORING; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT MANAGEMENT PROGRAM; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EARLY MEDICAL INTERVENTION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; OBESITY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WEIGHT REDUCTION PROGRAMS;

EID: 84896768593     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.592546     Document Type: Article

References (48)

1. Alvarez-Jiménez M, Gonzá lez-Blanch C, Vázquez- Barquero JL, P é rez-Iglesias R, Mart í nez-García O, Pé rez-Pardal T, et al. 2006. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry 67(8): 1253-1260.
2. Alvarez-Jiménez M, Hetrick SE, Gonz á lez-Blanch C, Gleeson JF, McGorry PD. 2008. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193(2):101-107.
3. Alvarez-Jiménez M, Martínez-García O, P érez-Iglesias R, Ram írez ML, V ázquez-Barquero JL, Crespo-Facorro B. 2010. Prevention of antipsychotic-induced weight gain with early behavioral intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res 116(1):16-9.
4. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ. 2005. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005;5:3.
5. Chen CK, Chen YC, Huang YS. 2009. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry Clin Neurosci 63(1):17-22.
6. Cordes J, Sinha-R ö der A, Kahl KG, Malevani J, Thuenker J, Lange-Asschenfeldt C, et al. 2008. Therapeutic options for weight management in schizophrenic patients treated with atypi cal antipsychotics. Fortschr Neurol Psychiatr 76(12): 703-714.
7. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. 2009. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 302(16):1765-1773; erratum: 302(21):2322.
8. Deutsche Gesellschaft f ür Ern ährunge V. 2006 Evidenzbasierte Leitlinie: Fettkonsum und Pr ävention ausgew ählter durch Ern ährung mitbedingter Krankheiten. Bonn (http://www.dge. de/leitlinie/).
9. Drieling T, Biedermann NC, Scharer LO, Strobl N, Langosch JM. 2007. Psychotropic drug-induced change of weight: a review. Fortschr Neurol Psychiatr 75(2):65-80. (Pubitemid 46586743)
10. Evans S, Newton R, Higgins S. 2005. Nutritional intervention to prevent weight gain in patients commenced on olancapine: a randomised controlled trial. Aust NZ J Psychiatry 39:479-486. (Pubitemid 40932626)
11. Faulkner G, Cohn T, Remington G. 2007. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 24(1): CD005148.
12. Feeney L, Dempsey J, Moynihan F, Barry S. 2003. Changes in body mass indices of patients with schizophrenia 3 years following the introduction of a weight management programme. Ir Med J 96(9):276-277.
13. Fenton WS, Chavez MR. 2006. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 163(10):697-704.
14. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. 2008. Comorbid somatic illnesses in patients with severe mental disorders: clini cal, policy, and research challenges. J Clin Psychiatry 69(4):514-519. (Pubitemid 351792324)
15. Gaur N, Grover S. 2010. Factors associated with weight gain with olanzapine. World J Biol Psychiatry 11(2):156-157.
16. Guy W. 1976. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health. p 218-222.
17. Haddad P. 2005. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19(6 Suppl): 16-27. (Pubitemid 44567855)
18. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. 2005. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62(1):19-28. (Pubitemid 40096067)
19. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. 2007. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32(2): 289-297. (Pubitemid 46106936)
20. Kantrowitz JT, Citrome L. 2008. Olanzapine: review of safety. Expert Opin Drug Saf 7(6):761-769.
21. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261-76. (Pubitemid 18039085)
22. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. 2005. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25(3):255-258. (Pubitemid 40685790)
23. Koponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, Isohanni MK, et al. 2010. The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry 11(2 Pt 2):262-267.
24. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, et al. 2006. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 67(4): 547-553. (Pubitemid 43764231)
25. Lachin JM. 1988. Statistical properties of randomization in clinical trials. Control Clin Trials 9(4):289-311. (Pubitemid 19012636)
26. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31-41.
27. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62(4): 361-370. (Pubitemid 40471685)
28. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. 2003. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 35(3):237-241. (Pubitemid 38591665)
29. McElroy SL. 2009. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry 70(Suppl 3):12-21.
30. McIntyre RS. 2009. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 70(6):e17.
31. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. 2004. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65(4):471-477.
32. Michaelis D, Rjasanowski I, Hildmann W, Kohnert KD, Richter KV. 1985. Validity of WHO criteria for classifi cation of newly diagnosed diabetics. Exp Clin Endocrinol 85(1):61-9. (Pubitemid 15112831)
33. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefi t equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(5 Suppl 1):S7-14.
34. Newcomer JW. 2007. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(Suppl 4):8-13. (Pubitemid 46762118)
35. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59(4):337-345. (Pubitemid 34275252)
36. Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. 2009. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 70(4):487-499.
37. Osby U, Correia N, Brandt L, Ekbom A, Spar én P. 2000. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45(1-2):21-28.
38. Pajonk FG, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I, et al. 2010. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 67(2):133-143.
39. Pendlebury J, Haddad P, Dursun S. 2005. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 20(6): 447-448. (Pubitemid 41269703)
40. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview: the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33. (Pubitemid 29001829)
41. Simon V, van Winkel R, De Hert M. 2009. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70(7): 1041-1050.
42. Smith M, Porter R. 2009. Antipsychotics and risk of diabetes in schizophrenia. Br J Psychiatry 194(2):186-187.
43. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. 2007. Impaired glucose tolerance in first-episode drug-na ïve patients with schizophrenia. Diabet Med 24(5):481-485. (Pubitemid 46669314)
44. Tandon R, Jibson MD. 2003. Effi cacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28(Suppl 1):9-26. (Pubitemid 36015659)
45. Thakore JH. 2005. Metabolic syndrome and schizophrenia. Br J Psychiatry 186:455-456. (Pubitemid 40834861)
46. Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, et al. 2009. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 10(4 Pt 3):729-740.
47. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. 2003. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 54(8): 1155-1157. (Pubitemid 36951518)
48. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. 2007. Outcomes of obese, clozapine-treated inpatients with schizophrenia plaxed on a six-month diet and physical activity program. Psychiatr Serv 58:544-550 (previous presentation at the 2nd European Conference on Schizophrenia Research, 21-23 September 2009, Berlin, Germany.